Trial Now Recruiting: Diagnosis and Treatment of Patients With Inborn Errors of Metabolism (NCT00369421)
WHY IT MATTERS
This trial offers patients with arterial calcification due to CD73 deficiency direct access to specialized NIH researchers and potential treatment options that may not be available elsewhere.
Researchers at the National Institutes of Health are looking for up to 4,000 patients with rare metabolic disorders to study and treat. These are conditions where the body cannot properly break down certain substances because of missing or faulty proteins. Patients will receive exams and treatment, mostly as outpatients, though some may need to stay at the NIH Clinical Center for special tests.
NCT ID: NCT00369421 Status: RECRUITING Conditions: Arterial Calcification Due to Deficiency of CD73 Enrollment: 4000 Sponsor: National Human Genome Research Institute (NHGRI) Summary: Researchers intend on diagnosing and treating certain inborn errors of metabolism. By doing this researchers hope to expand their knowledge about these disorders and provide access to patients of interest for research, teaching, and clinical experience. Patients participating in this study will be examined and treated on an out patient basis, if practical. However, patients requiring specialized tests or treatments will be admitted to the NIH Clinical Center as necessary. Researchers will use o
YOU CAN ACT ON THIS
If you or a family member has been diagnosed with arterial calcification due to CD73 deficiency or another inborn error of metabolism, contact the NIH Clinical Center directly using the trial ID NCT00369421 to ask about enrollment eligibility and next steps.